Table 1.
Biologics trials evidences in Crohn's disease
| Induction | Maintenance | Fistulizing | Mucosal healing | Combination | Combination | Rescuea | ||
|---|---|---|---|---|---|---|---|---|
| thiopurine | methotrexate | |||||||
| Anti-TNF alpha | ||||||||
| Infliximab | + | + | + | + | + | − | NA | |
| Adalimumab | + | + | + | + | +/− | NA | + | |
| Certolizumab | + | + | + | # | NA | NA | + | |
| Golimumab | NA | NA | NA | NA | NA | NA | NA | |
| Anti-integrin | ||||||||
| Natalizumab | + | + | NA | NA | NA | NA | NA | |
| Vedolizumab | + | + | NA | NA | NA | NA | + | |
| Others | ||||||||
| Ustekinumab (phase IIb) | + | + | NA | NA | NA | NA | + | |
a
Efficacy of the treatment in patients who have failed previous biologics treatment.
NA: Study is not available.
+: Study is available with a positive outcome.
−: Study is available with a negative outcome.
+/−: Retrospective studies.
#: Study with a positive outcome but not comparing with placebo.